科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background The treatment of worsening Multiple Sclerosis (MS) remains challenging Mitoxantrone, an anthracyclines is approved as a treatment for worsening MS However systematic analyses of its tolerability and effectiveness outside of controlled trials are few Certain advantages including easy application and simple monitoring need to be balanced against its toxicity
Objective To study efficacy tolerability and feasibility of mitoxantrone treatment in a regular clinical setting
Methods Retrospective analysis of data from 96 MS patients with worsening MS before during and after mitoxantrone Specifically we addressed adherence and reasons for deviations from the intended treatment schedule regarding tolerability and safety and consequences of deviations on clinical efficacy
Results Schedule deviations were frequent Only a third of patients received the intended cumulative dose Hematological toxicity was generally mild and transient In 7 patients treatment was withheld because of impact on ventricular ejection fraction in the absence of clinical symptoms of cardiac failure No malignancies were observed With respect to clinical benefit most patients remained stable and the relapse rate decreased with mitoxantrone initiation in both relapsing and secondary MS patients (p < 0 0001) A possible modest non-significant dose-effect on annualized relapse rates was observed
Conclusion Mitoxantrone may be considered for treatment of refractory MS Poor tolerability impacted adherence but dose-limiting safety events were rare Mitoxantrone needs to be carefully assessed in light of recent data on risk of cardiotoxicity and leukemia Published by Elsevier B V
- 出版日期2010-12
